Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Core Insights - Abeona Therapeutics Inc. reported strong figures for Q3 2025, with a GAAP EPS of -$0.10, surpassing expectations by $0.18, leading to a 22% increase in stock price post-announcement [1] Financial Performance - The company achieved a GAAP EPS of -$0.10 for Q3 2025, which was better than the anticipated figure by $0.18 [1] - The stock price rose by 22% following the announcement of these results [1] Company Background - Abeona Therapeutics is focused on biotechnology, particularly in drug development, with an emphasis on innovative therapies and unique mechanisms of action [1]